Article Text

Download PDFPDF

Considering biosimilars in inflammatory diseases
  1. Iain McInnes
  1. Correspondence to Iain McInnes, Institute of Infection, Immunity and Inflammation, University of Glasgow, Scotland, UK, iain.mcinnes{at}glasgow.ac.uk

Statistics from Altmetric.com

With the projected expansion of the biosimilars market, clinicians must assimilate many important issues. These include understanding biosimilar development, building strategies for biosimilar introduction, and developing robust systems for biosimilar pharmacovigilance. With ten tumour necrosis factor inhibitors, a first rituximab biosimilar now on the market, and many more biosimilars currently in development, controversial issues such as multiple biosimilar switching and indication extrapolation also require consideration.

In ‘The Biosimilar Approval Process: How different is it?’, Isaacs et al explore the sophisticated biosimilar manufacturing process and the regulatory requirements for …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.